- 行業(yè)新聞
-
上海翻譯公司完成解說(shuō)詞英文翻譯
發(fā)布時(shí)間：2018-02-23 10:31 點(diǎn)擊：
上海翻譯公司完成解說(shuō)詞英文翻譯
一、歷史與榮耀history and honor在中國(guó)，“北京協(xié)和”，早已成為值得信賴(lài)的象征和家喻戶(hù)曉的品牌。北京協(xié)和藥廠，隸屬于中國(guó)醫(yī)學(xué)科學(xué)院藥物研究所，創(chuàng)立于1958年.秉承嚴(yán)謹(jǐn)?shù)目萍紕?chuàng)新精神，經(jīng)過(guò)半個(gè)多世紀(jì)的發(fā)展，北京協(xié)和藥廠已成為北京市高新技術(shù)企業(yè)、“瞪羚計(jì)劃”首批重點(diǎn)培育企業(yè)、標(biāo)準(zhǔn)創(chuàng)新試點(diǎn)單位和北京市專(zhuān)利示范單位，并納入中央國(guó)有資本經(jīng)營(yíng)預(yù)算實(shí)施范圍。依托中國(guó)醫(yī)學(xué)科學(xué)院藥物研究所的強(qiáng)大研發(fā)實(shí)力，北京協(xié)和藥廠先后上市了多個(gè)擁有自主知識(shí)產(chǎn)權(quán)的原研產(chǎn)品，是國(guó)內(nèi)為數(shù)不多的有原研化學(xué)藥物制劑出口海外的制藥企業(yè)，以多個(gè)原研藥物為代表的“協(xié)和”品牌，已成為民族制藥業(yè)“中國(guó)創(chuàng)造”的典范。北京協(xié)和藥廠不僅承擔(dān)著企業(yè)自身發(fā)展的重任，還立志推動(dòng)中國(guó)民族制藥業(yè)的進(jìn)步與發(fā)展，每個(gè)協(xié)和人為之奮斗、為之自豪！In China, ‘Beijing Union’ has been a famous and trustworthy brand for quite a long time. Beijing Union Pharmaceutical Factory was founded in 1958 and is subordinate to Institute of Materia Medica (IMM), Chinese Academy of Medical Sciences & Peking Union Medical College. With the spirit of rigorous technology innovation in the development forAfter more than half-century, it has been listed as a new & high-tech enterprise in Beijing City, one of the first cultivated high-growth medium-sized and smallmedium-and-small-sized enterprises, standard innovation pilot unit and Beijing patent demonstration unit it was incorporated into the scope of central state-owned capital management budget implementation. Depending on strong innovation and research strength from IMM, we focus on creation and production of innovative drugs with proprietary intellectual property rights. It is one of few Chinese factories who export its innovative chemical preparations. Presented by multiple innovative drugs, “Union” brand has been the sample of “created in China” in national pharmaceutical industry. With its development, the factory also promotes progress and development for national pharmaceutical industry, for which every staff of “Union” has been striving for and proud of. .二、發(fā)展與優(yōu)勢(shì)Development and Strength五十余年來(lái)，秉承“以質(zhì)量求生存，以科技創(chuàng)新求發(fā)展，為人類(lèi)的健康事業(yè)作貢獻(xiàn)”的企業(yè)宗旨，北京協(xié)和藥廠已經(jīng)從肇建之始的新藥中試基地成長(zhǎng)為集研發(fā)、生產(chǎn)、營(yíng)銷(xiāo)為一體的高科技制藥企業(yè)。It was just a new drug pilot plant fifty years ago, but now it becomes a new & high-tech enterprise with tenet of "surviving by good quality, seeking development by innovation and making a contribution to improve contributing to improving human health", covering business scope of medical research R&D, production and marketing.1、 強(qiáng)大的研發(fā)與產(chǎn)業(yè)化實(shí)力 北京協(xié)和藥廠建有北京市企業(yè)技術(shù)中心，先后承擔(dān)完成國(guó)家高技術(shù)產(chǎn)業(yè)發(fā)展項(xiàng)目、國(guó)家“863”計(jì)劃項(xiàng)目、北京市高新技術(shù)成果轉(zhuǎn)化項(xiàng)目、北京市工業(yè)發(fā)展資金項(xiàng)目等國(guó)家級(jí)、省部級(jí)新藥研發(fā)和產(chǎn)業(yè)化專(zhuān)項(xiàng)。“雙環(huán)醇的研究”更是獲得了“2007年度國(guó)家科技進(jìn)步二等獎(jiǎng)”的殊榮。“十一五”期間，藥廠又承擔(dān)或參與了三項(xiàng)國(guó)家“重大新藥創(chuàng)制”科技重大專(zhuān)項(xiàng)課題，進(jìn)一步全面提升了企業(yè)自主創(chuàng)新及科研成果產(chǎn)業(yè)化能力。1. Strong strength in research and industrializationIn addition, The the factory also has an enterprise technology R&D center; we have undertakenundertake and accomplished some important national and provincial levels projects on new drug research and industrialization, such as national high technology industry development project, national ‘863’ plan poject’, Beijing high-tech achievement transformation project, Beijing industry development fund project, etc. “BICYCLOL RESEARCHThe research on Bicyclol” was awarded second National Prize for Progress in Science and Technology in 2007. During “Eleventh Five-year Plan” period, we undertook and participated in three science and technology subjects of national "major new drug creation" projects, which comprehensively upgraded the capacityability of enterprise independent innovation and industrialization of research findings.2、 完善的質(zhì)量保證控制體系 北京協(xié)和藥廠擁有完善的質(zhì)量保證和質(zhì)量控制體系，建有通過(guò)國(guó)家GMP認(rèn)證的多個(gè)化學(xué)原料藥及片劑、膠囊劑、滴丸劑、乳膏劑、小容量注射劑、凍干粉針劑等多種劑型生產(chǎn)線(xiàn)，并通過(guò)ISO 14001環(huán)境管理體系認(rèn)證和北京市清潔生產(chǎn)審核。2. Perfect quality control systemWe established perfect quality assurance and quality control systems, all production lines for chemical bulk drug, tablets, capsules, pills, creams, small volume injections (including anti-tumor class) and freeze-dried powder injections (antineoplastic agents) have got China GMP certification, as well as ISO 14001 Environment Management System Certification and Beijing Clean Production Audit.3、 創(chuàng)新原研的產(chǎn)品系列 依托國(guó)家級(jí)新藥研究機(jī)構(gòu)——中國(guó)醫(yī)學(xué)科學(xué)院藥物研究所強(qiáng)大的藥物研發(fā)實(shí)力，北京協(xié)和藥廠致力于引進(jìn)和開(kāi)發(fā)具有高科技含量和自主知識(shí)產(chǎn)權(quán)的創(chuàng)新藥物，陸續(xù)上市了多個(gè)世界首創(chuàng)的原研品種，如百賽諾 (雙環(huán)醇片)、甲異靛片、聯(lián)苯雙酯滴丸、葛根素注射液、三尖杉酯堿注射液、高三尖杉酯堿注射液、靈孢多糖注射液、酞丁安乳膏等，產(chǎn)品囊括了抗肝炎藥系列、抗腫瘤藥系列以及心腦血管藥系列等。其中，百賽諾——我國(guó)第一個(gè)上市的具有國(guó)際自主知識(shí)產(chǎn)權(quán)的一類(lèi)化學(xué)新藥，由中國(guó)醫(yī)學(xué)科學(xué)院藥物研究所創(chuàng)制、北京協(xié)和藥廠獨(dú)家生產(chǎn)，2001年上市并享有12年新藥保護(hù)期。該藥適用于伴有氨基轉(zhuǎn)移酶升高的慢性病毒性肝炎和非病毒性肝病的保肝抗炎治療，是中華醫(yī)學(xué)會(huì)《慢性乙型肝炎防治指南》、《酒精性肝病診療指南》和《非酒精性脂肪性肝病診療指南》的推薦用藥，列入《中國(guó)高新技術(shù)產(chǎn)品目錄》、國(guó)家及各省級(jí)《基本醫(yī)療保險(xiǎn)、工傷保險(xiǎn)和生育保險(xiǎn)藥品目錄》和《軍隊(duì)合理醫(yī)療藥品目錄》。3. Innovative productsInnovation products seriousDepending on strong innovative resource and scientific research strength from IMM, we focus on introduction and development of innovative drugs with high-tech content and proprietary intellectual property rights. We launched many innovative drugs which were firstly put in the market internationally, including a series serious of anti hepatitis, antineoplastic and cardiovascular drugs, such as Bicyclol Tablets, Meisoindigo Tablets, bifendate pilules, harringtonine injection, Homoharringtonine injection, Polysaccharidum of G. Lucidum Karst Injection and Ftibamzone cream. Among these drugs, Bicyclol tablets were launched in 2001 and have 12 years of new drug protection period. Bicyclol was created by IMM and produced by Beijing Union Pharmaceutical Factory exclusively, which was the first Chinese innovated chemical drug with international independent intellectual property right in China. Bicyclol is suitable for the treatment of chronic viral hepatitis associated with elevated serum transaminase abnormalities and non viral liver disease. Bicyclol is listed in <Alcoholic liver disease diagnosis and treatment guidelines>, < Nonalcoholic fatty liver disease diagnosis and treatment guidelines >, < Chronic Hepatitis B Prevention and Control Guideline> issued by Chinese Medical Association, and inlisted into <China’s high-tech Products Directory>, and < The National Basic Medical Insurance, Industrial Injury Insurance and Maternity Insurance Drug Catalogue, Catalogue of Drugs for Reasonable Military Medical Treatment. >.4、 專(zhuān)業(yè)的學(xué)術(shù)推廣 針對(duì)產(chǎn)品的學(xué)術(shù)推廣，北京協(xié)和藥廠在全國(guó)建立起一支專(zhuān)業(yè)、規(guī)范、高效的營(yíng)銷(xiāo)隊(duì)伍，以臨床需求為導(dǎo)向，以產(chǎn)品特性為核心，以客戶(hù)服務(wù)為保障，獲得了臨床醫(yī)生的廣泛認(rèn)可。優(yōu)良的產(chǎn)品質(zhì)量和高端的國(guó)際交流也為北京協(xié)和藥廠進(jìn)軍海外市場(chǎng)開(kāi)辟了通道。目前，百賽諾、聯(lián)苯雙酯滴丸、酞丁安乳膏等產(chǎn)品已登陸烏克蘭、哈薩克斯坦、烏茲別克斯坦、韓國(guó)、埃及、越南、緬甸等國(guó)家，成為中國(guó)化學(xué)藥品制劑走向國(guó)際的典范，獲得了海外眾多醫(yī)患的贊譽(yù)。4. Professional academic promotionWe have a professional well-behaved marketing team with high efficiency in China for academic promotion of products., Now many products have been widely acknowledged by clinicians.With quality advantages of products and international high-end communications, Bicyclol tablets, bifendate pills and Ftibamzone cream have been sold domestically and internationally, including in Ukraine, Kazakhstan, Uzbekistan, Kyrghizstan, Tadzhikistan, Georgia, Egypt, Republic of Korea, Viet Nam and Myanmar, etc.三、愿景與展望Vision and Prospect立足國(guó)內(nèi)，放眼海外，致力打造“中國(guó)創(chuàng)造”品牌，北京協(xié)和藥廠以百賽諾作為龍頭產(chǎn)品，近五年的凈利潤(rùn)復(fù)合增長(zhǎng)率超過(guò)40%。We will keep Bicyclol as our flagship product to build the brand of ‘created in China’ home and abroad, and for five years have accompishedearn more than 40% of compound growth rate of net profits by more than 40%.根據(jù)企業(yè)長(zhǎng)遠(yuǎn)發(fā)展的需要，北京協(xié)和藥廠斥資5億元，在中關(guān)村科技園區(qū)大興生物醫(yī)藥產(chǎn)業(yè)基地建設(shè)全新廠區(qū)，預(yù)計(jì)于2014年年底前全部投入使用，屆時(shí)將建成國(guó)內(nèi)領(lǐng)先、與國(guó)際接軌、達(dá)到歐盟GMP要求的現(xiàn)代化藥品生產(chǎn)基地。According to enterprise long-term development requirement, we are building a brand new plantproduction base in Daxing Biomedical Industry Base of Zhongguancun Science and Technology Park the area of both Zhongguancun national Independent innovation demonstration zone and Beijing Bio-Engineering and Pharmaceutical Industrial Base. In the end of 2014, when it is put into service, it will be a modern pharmaceutical production base, in line with international standards and reach the EU GMP requirements.此外，雙環(huán)醇新型制劑、雙功能紫杉醇共綴物、S1P1受體選擇性激動(dòng)劑、用于治療老年性癡呆的天麻芐醇酯苷、抗焦慮藥布格呋喃等創(chuàng)新藥物的研發(fā)近期有望取得突破，將為企業(yè)的可持續(xù)發(fā)展增添更多新的動(dòng)力。In addition, some of new drug research and development projects will make a breakthrough recently, including new preparation of Bicyclol, bifunctional paclitaxel altogether compose objects, S1P1 selective agonist receptor, Gastrodia elata benzyl alcohol ester glycosides for treatment for senile dementia, antianxietic Bouguer furan, etc., which will add more new momentum for the enterprise's sustainable development.{藥物研究所蔣建東所長(zhǎng)專(zhuān)訪：中國(guó)醫(yī)學(xué)科學(xué)院藥物研究所下轄北京協(xié)和藥廠、北京協(xié)和制藥二廠、北京聯(lián)馨藥業(yè)有限公司、北京協(xié)和建昊醫(yī)藥技術(shù)開(kāi)發(fā)有限責(zé)任公司、國(guó)家新藥開(kāi)發(fā)工程技術(shù)研究中心等產(chǎn)業(yè)實(shí)體，涵蓋了新藥創(chuàng)制上下游從藥物開(kāi)發(fā)、評(píng)價(jià)、中試放大到產(chǎn)業(yè)化的較為完整的產(chǎn)業(yè)鏈條，在產(chǎn)學(xué)研資源、技術(shù)的整合，建立“以企業(yè)為主體”“產(chǎn)學(xué)研結(jié)合”的新藥創(chuàng)制體系方面具有優(yōu)良的傳統(tǒng)和獨(dú)到的優(yōu)勢(shì)。Exclusive interview to president of IMM: There are several IMM-owned enterprises manufacturing drug products and providing technical services. They are Beijing Union Pharmaceutical Factory, Beijing Union Second Pharmaceutical Factory, Beijing LianXin Pharmaceutical Co., Ltd., Beijing Union Jianhao -Genius Pharmaceutical Development Technology Co., Ltd.,Chinese National New Medicine Development Engineering Research Center Beijing Collab Pharma Co., Ltd. All of them have formulated a complete industry chain covering new medicine R&D, evaluation, pilot-scale experiment and production. In general, IMM has fine traditions and unique advantages in integration of industry-university-research cooperation resources and technology to establishing new medicine creation system in enterprises. through combination of basic research and R&D application, IMM serves the nation and patients with new drugs as well as industrial drug production.“十二五”期間，依托中國(guó)醫(yī)學(xué)科學(xué)院藥物研究所的技術(shù)與人力資源，我們將整體投資15億元在中關(guān)村科技園區(qū)大興生物醫(yī)藥產(chǎn)業(yè)基地建設(shè)“中國(guó)醫(yī)學(xué)科學(xué)院藥物研究所創(chuàng)新藥物產(chǎn)學(xué)研基地”，項(xiàng)目的主要特點(diǎn)為：企業(yè)為主、校企共建、開(kāi)放共享。我們將整合中國(guó)醫(yī)學(xué)科學(xué)院藥物研究所產(chǎn)學(xué)研技術(shù)及資源優(yōu)勢(shì)，按照國(guó)際新藥創(chuàng)制的通行做法，打造一流的產(chǎn)業(yè)化基地以及產(chǎn)學(xué)研共建的平臺(tái)，真正建立由企業(yè)帶動(dòng)科研機(jī)構(gòu)、以市場(chǎng)為導(dǎo)向、產(chǎn)學(xué)研緊密結(jié)合的創(chuàng)新藥物研究開(kāi)發(fā)模式，提高集成創(chuàng)新能力，提高新藥研發(fā)的效率，建立真正意義上的產(chǎn)業(yè)聯(lián)盟，加快創(chuàng)新藥物的產(chǎn)業(yè)化進(jìn)程。During the 12th Five-year Plan period, we, with the help of technology and human resource of IMM, will invest 1.5 billion yuan to build an industry-university-research cooperation base of innovative medicine, which is attached to IMM, in Daxing Biomedical Industry Base of Zhongguancun Science and Technology Park. The main feature of the project is that it will be co-constructed by enterprise and university while be played by enterprise. We will integrate technology and resource advantages of IMM, follow the international routine practiced in new medicine creation, and forge the first-rate industrialized base and platform for industry-university-research cooperation. Based on the marked-oriented, enterprise-driven and industry-university-research cooperated mechanism, it is actually hoped to establish a development model for innovative medicine research to enhance innovative capacity and R&D efficiency and to speed up industrialization of innovative medicine by building up industry alliance.an innovative drug production base combining R&D, with total investment of 1.5 billion RMB.dedicate to innovation and development, maintain positive and steady operation, to build modern manufacturing sites for Beijing Union Pharmaceutical Factory and Beijing Union Second Pharmaceutical Factory, and a industry-university-research cooperation base of innovative drugs for IMM in the area of both Zhongguancun national Independent innovation demonstration zone and Beijing Bio-Engineering and Pharmaceutical Industrial Basewith the market-driven economy,同時(shí)，北京協(xié)和藥廠正在探索實(shí)施企業(yè)改制，引入新的經(jīng)營(yíng)思路，構(gòu)建全新的運(yùn)營(yíng)機(jī)制，以進(jìn)一步提升企業(yè)的核心競(jìng)爭(zhēng)力。深入貫徹科學(xué)發(fā)展觀，著力強(qiáng)化企業(yè)技術(shù)創(chuàng)新主體地位， 深化科技體制改革，是中國(guó)醫(yī)學(xué)科學(xué)院藥物研究所及其下屬企業(yè)義不容辭的責(zé)任！}Beijing Union Pharmaceutical factory is exploring restructuring of enterprise to introduce new management idea and construct new operational mechanism to enhance core competitiveness further. To strengthen technological innovation in enterprise and to deepen institutional reform of science and technology, which are also in line with Scientific Outlook on Development, are obligatory duties for IMM and its subordinate enterprises.體制的改革必將帶來(lái)企業(yè)更快的發(fā)展，展望“十二五”，北京協(xié)和藥廠將緊緊圍繞改革、創(chuàng)新、發(fā)展的主題，與藥物研究所共建國(guó)內(nèi)領(lǐng)先水平的“創(chuàng)新藥物產(chǎn)學(xué)研基地”，把握醫(yī)藥產(chǎn)業(yè)政策導(dǎo)向，實(shí)現(xiàn)國(guó)有資產(chǎn)持續(xù)增值，躋身先進(jìn)制藥企業(yè)行列，為國(guó)家實(shí)現(xiàn)醫(yī)藥強(qiáng)國(guó)的重大戰(zhàn)略做出更新、更大的貢獻(xiàn)！Institutional reform will bring faster development for the enterprises. During the 12th Five-year Plan period, by following the theme of reform, innovation and development, we will build ana industry-university-research cooperation base of innovative drugs together with IMM, and achieve steady increase in value for the state-owned assets. It is hoped that we could stand in the advanced pharmaceutical enterprises and make a great contribution to the national grand strategy of becoming an international medical power.t世聯(lián)翻譯-讓世界自由溝通！專(zhuān)業(yè)的全球語(yǔ)言翻譯供應(yīng)商，上海翻譯公司專(zhuān)業(yè)品牌。絲路沿線(xiàn)56種語(yǔ)言一站式翻譯與技術(shù)解決方案，專(zhuān)業(yè)英語(yǔ)翻譯、日語(yǔ)翻譯等文檔翻譯、同傳口譯、視頻翻譯、出國(guó)外派服務(wù)，加速您的全球交付。 世聯(lián)翻譯公司在北京、上海、深圳等國(guó)際交往城市設(shè)有翻譯基地，業(yè)務(wù)覆蓋全國(guó)城市。每天有近百萬(wàn)字節(jié)的信息和貿(mào)易通過(guò)世聯(lián)走向全球！積累了大量政商用戶(hù)數(shù)據(jù)，翻譯人才庫(kù)數(shù)據(jù)，多語(yǔ)種語(yǔ)料庫(kù)大數(shù)據(jù)。世聯(lián)品牌和服務(wù)品質(zhì)已得到政務(wù)防務(wù)和國(guó)際組織、跨國(guó)公司和大中型企業(yè)等近萬(wàn)用戶(hù)的認(rèn)可。
上海翻譯公司完成解說(shuō)詞英文翻譯
